ZA200007653B - Characterisation of gene function using double stranded RNA inhibition. - Google Patents
Characterisation of gene function using double stranded RNA inhibition. Download PDFInfo
- Publication number
- ZA200007653B ZA200007653B ZA200007653A ZA200007653A ZA200007653B ZA 200007653 B ZA200007653 B ZA 200007653B ZA 200007653 A ZA200007653 A ZA 200007653A ZA 200007653 A ZA200007653 A ZA 200007653A ZA 200007653 B ZA200007653 B ZA 200007653B
- Authority
- ZA
- South Africa
- Prior art keywords
- dna
- promoter
- transcription factor
- organism
- vector
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 120
- 108090000623 proteins and genes Proteins 0.000 title claims description 115
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims description 78
- 230000005764 inhibitory process Effects 0.000 title description 8
- 238000012512 characterization method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 129
- 239000013598 vector Substances 0.000 claims description 128
- 108020004414 DNA Proteins 0.000 claims description 117
- 108091023040 Transcription factor Proteins 0.000 claims description 75
- 102000040945 Transcription factor Human genes 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 63
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 60
- 230000014509 gene expression Effects 0.000 claims description 52
- 239000013612 plasmid Substances 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 49
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 239000002299 complementary DNA Substances 0.000 claims description 43
- 238000013518 transcription Methods 0.000 claims description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- 230000035897 transcription Effects 0.000 claims description 42
- 230000009261 transgenic effect Effects 0.000 claims description 41
- 241000588724 Escherichia coli Species 0.000 claims description 37
- 238000010367 cloning Methods 0.000 claims description 24
- 241000244206 Nematoda Species 0.000 claims description 22
- 238000002474 experimental method Methods 0.000 claims description 21
- 230000000977 initiatory effect Effects 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 18
- 238000001086 yeast two-hybrid system Methods 0.000 claims description 18
- 230000010354 integration Effects 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 14
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 13
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 13
- 230000000692 anti-sense effect Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 230000033228 biological regulation Effects 0.000 claims description 10
- 241000607479 Yersinia pestis Species 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 101150015886 nuc-1 gene Proteins 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 7
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 101150110777 let-858 gene Proteins 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 230000009466 transformation Effects 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 101100459320 Caenorhabditis elegans myo-2 gene Proteins 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 5
- 108700008625 Reporter Genes Proteins 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 206010061217 Infestation Diseases 0.000 claims description 4
- 101150117157 MYO3 gene Proteins 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 238000010396 two-hybrid screening Methods 0.000 claims description 3
- 241000380490 Anguina Species 0.000 claims description 2
- 241000294569 Aphelenchoides Species 0.000 claims description 2
- 241000580217 Belonolaimus Species 0.000 claims description 2
- 241000243770 Bursaphelenchus Species 0.000 claims description 2
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 2
- 241000399934 Ditylenchus Species 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 241001442498 Globodera Species 0.000 claims description 2
- 241001480224 Heterodera Species 0.000 claims description 2
- 241001540513 Hoplolaimus Species 0.000 claims description 2
- 241001220360 Longidorus Species 0.000 claims description 2
- 241001143352 Meloidogyne Species 0.000 claims description 2
- 241000201433 Nacobbus Species 0.000 claims description 2
- 241001220391 Paratrichodorus Species 0.000 claims description 2
- 241000193943 Pratylenchus Species 0.000 claims description 2
- 241000201377 Radopholus Species 0.000 claims description 2
- 241001540480 Rotylenchulus Species 0.000 claims description 2
- 241001220308 Trichodorus Species 0.000 claims description 2
- 241001267618 Tylenchulus Species 0.000 claims description 2
- 101150033660 UL6 gene Proteins 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 description 24
- 230000009368 gene silencing by RNA Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 17
- 230000006870 function Effects 0.000 description 14
- 238000010276 construction Methods 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 238000011176 pooling Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000003071 parasitic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 101100528916 Caenorhabditis elegans rol-6 gene Proteins 0.000 description 3
- 101100048437 Caenorhabditis elegans unc-22 gene Proteins 0.000 description 3
- 101100243717 Cochliobolus carbonum PGN1 gene Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101150066002 GFP gene Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 101100016388 Arabidopsis thaliana PAS2 gene Proteins 0.000 description 2
- 101100011366 Caenorhabditis elegans egl-15 gene Proteins 0.000 description 2
- 101100071585 Caenorhabditis elegans hsp-16.2 gene Proteins 0.000 description 2
- 101100074836 Caenorhabditis elegans lin-22 gene Proteins 0.000 description 2
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 101100297150 Komagataella pastoris PEX3 gene Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101100315760 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX4 gene Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 101150086731 ges-1 gene Proteins 0.000 description 2
- 230000010196 hermaphroditism Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150114748 unc-119 gene Proteins 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 101150029062 15 gene Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101100064098 Caenorhabditis elegans dpy-7 gene Proteins 0.000 description 1
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 101150046414 ce gene Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 101150034492 gdhA-2 gene Proteins 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10241—Use of virus, viral particle or viral elements as a vector
- C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Catching Or Destruction (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9814536.0A GB9814536D0 (en) | 1998-07-03 | 1998-07-03 | Characterisation of gene function using double stranded rna inhibition |
| GBGB9827152.1A GB9827152D0 (en) | 1998-07-03 | 1998-12-09 | Characterisation of gene function using double stranded rna inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200007653B true ZA200007653B (en) | 2002-09-19 |
Family
ID=26313977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200007653A ZA200007653B (en) | 1998-07-03 | 2000-12-19 | Characterisation of gene function using double stranded RNA inhibition. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20030061626A1 (OSRAM) |
| EP (5) | EP1197567B2 (OSRAM) |
| JP (3) | JP4353639B2 (OSRAM) |
| KR (4) | KR20070041607A (OSRAM) |
| CN (3) | CN1198938C (OSRAM) |
| AT (2) | ATE433500T1 (OSRAM) |
| AU (1) | AU769223B2 (OSRAM) |
| BR (1) | BR9911802A (OSRAM) |
| CA (2) | CA2789083C (OSRAM) |
| CY (2) | CY1108920T1 (OSRAM) |
| CZ (2) | CZ304897B6 (OSRAM) |
| DE (5) | DE69940984D1 (OSRAM) |
| DK (2) | DK1484415T3 (OSRAM) |
| ES (2) | ES2327334T3 (OSRAM) |
| GB (4) | GB9827152D0 (OSRAM) |
| HU (1) | HU230602B1 (OSRAM) |
| IL (3) | IL140467A0 (OSRAM) |
| IN (2) | IN2001DE00006A (OSRAM) |
| IS (1) | IS2816B (OSRAM) |
| MX (1) | MX234065B (OSRAM) |
| NO (1) | NO327729B1 (OSRAM) |
| NZ (1) | NZ509182A (OSRAM) |
| PL (3) | PL201425B1 (OSRAM) |
| PT (2) | PT1197567E (OSRAM) |
| RU (1) | RU2240349C2 (OSRAM) |
| WO (1) | WO2000001846A2 (OSRAM) |
| ZA (1) | ZA200007653B (OSRAM) |
Families Citing this family (257)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| KR101085210B1 (ko) | 1998-03-20 | 2011-11-21 | 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 | 유전자 발현 조절방법 |
| GB9827152D0 (en) * | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP2314700A1 (en) * | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7601494B2 (en) | 1999-03-17 | 2009-10-13 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
| EP1171586B1 (en) * | 1999-04-21 | 2013-06-12 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
| US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
| US6924109B2 (en) * | 1999-07-30 | 2005-08-02 | Agy Therapeutics, Inc. | High-throughput transcriptome and functional validation analysis |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| GB9930691D0 (en) * | 1999-12-24 | 2000-02-16 | Devgen Nv | Improvements relating to double-stranded RNA inhibition |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| WO2005041859A2 (en) | 2003-04-30 | 2005-05-12 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery. |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| NZ522045A (en) | 2000-03-30 | 2007-05-31 | Whitehead Biomedical Inst | RNA sequence-specific mediators of RNA interference |
| GB2362383B (en) * | 2000-05-19 | 2003-12-31 | Devgen Nv | Gene expression system |
| GB0012229D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Lipid uptake assays |
| US7083947B2 (en) | 2000-05-19 | 2006-08-01 | Devgen Nv | Assay techniques using nematode worms |
| GB0012233D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Vector constructs |
| AU2001275474A1 (en) * | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| EP1392857B1 (en) * | 2001-01-25 | 2010-01-20 | VIRxSYS Corporation | Methods and compositions for identifying gene function |
| NZ526507A (en) | 2001-01-26 | 2005-07-29 | Commw Scient Ind Res Org | Methods and means for producing efficient silencing construct using recombinational cloning |
| EP1229134A3 (en) | 2001-01-31 | 2004-01-28 | Nucleonics, Inc | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| EP1364066A2 (en) * | 2001-02-02 | 2003-11-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying functional nucleic acids |
| WO2005078097A2 (en) | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003070888A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
| JP4358521B2 (ja) | 2001-05-18 | 2009-11-04 | サーナ・セラピューティクス・インコーポレイテッド | 細胞デリバリーのためのコンジュゲートおよび組成物 |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7691995B2 (en) | 2001-07-12 | 2010-04-06 | University Of Massachusetts | In vivo production of small interfering RNAS that mediate gene silencing |
| US7612194B2 (en) * | 2001-07-24 | 2009-11-03 | Monsanto Technology Llc | Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof |
| DE60236095D1 (de) | 2001-08-31 | 2010-06-02 | Riken Wako | PFLANZENSYSTEM ZUR UMFASSENDEN GENFUNKTIONSANALYSE UNTER VERWENDUNG EINER VOLLÄNGEN-cDNA |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| US20030150017A1 (en) * | 2001-11-07 | 2003-08-07 | Mesa Jose Ramon Botella | Method for facilitating pathogen resistance |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| WO2003064621A2 (en) * | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| EP2351836B1 (en) | 2002-02-01 | 2015-09-09 | Life Technologies Corporation | Double-stranded oligonucleotides |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003213054A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003219833A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1474433A4 (en) * | 2002-02-20 | 2005-02-23 | Sirna Therapeutics Inc | VALIDATION AND IDENTIFICATION OF RNA INTERFERENCE FACILITATED TARGETS USING SHORT INTERFERENT NUCLEIC ACID (siNA) |
| US7667029B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
| AU2003216255A1 (en) * | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
| AU2003228667A1 (en) * | 2002-04-22 | 2003-12-19 | Sirna Therapeutics Inc. | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
| US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
| AU2003239851A1 (en) * | 2002-05-08 | 2003-11-11 | Xantos Biomedicine Ag | Expression constructs for producing double-stranded (ds) rna and the use thereof |
| AU2003239706A1 (en) * | 2002-05-23 | 2003-12-12 | Devgen Nv | Method for determining the influence of a compound on cholesterol transport |
| AU2003243094B2 (en) * | 2002-06-21 | 2007-08-30 | Sinogenomax Company Ltd. | Randomised DNA libraries and double-stranded RNA libraries, use and method of production thereof |
| BR0312580A (pt) * | 2002-07-10 | 2006-10-10 | Univ Kansas State | composições e métodos para controlar nematódeos parasitas |
| US7655790B2 (en) | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
| ATE350473T2 (de) | 2002-08-05 | 2007-01-15 | Atugen Ag | Weitere neue formen von interferierende rns moleküle |
| WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| US20040198967A1 (en) * | 2002-09-04 | 2004-10-07 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth | Compositions and methods for tissue specific or inducible inhibition of gene expression |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1613723B1 (en) | 2002-11-27 | 2013-05-15 | Sequenom, Inc. | Fragmentation-based methods for sequence variation detection and discovery |
| EP1597361A2 (en) * | 2002-12-23 | 2005-11-23 | Devgen NV | Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases and nucleotide sequences encoding such kinase sequences |
| IL155783A (en) | 2003-05-05 | 2010-11-30 | Technion Res & Dev Foundation | Multicellular systems of multi-potential embryonic human stem cells and cancer cells and their use |
| JP4884224B2 (ja) | 2003-05-09 | 2012-02-29 | ディアデクサス インコーポレーテッド | Ｏｖｒ１１０抗体組成物および使用方法 |
| EP1644494A2 (en) * | 2003-06-17 | 2006-04-12 | Devgen NV | Alcohol dehydrogenase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases |
| WO2005024068A2 (en) | 2003-09-05 | 2005-03-17 | Sequenom, Inc. | Allele-specific sequence variation analysis |
| PL1687435T3 (pl) * | 2003-11-17 | 2012-02-29 | Bayer Cropscience Nv | Odporność na owady z użyciem hamowania ekspresji genów |
| CN102989009B (zh) | 2003-12-31 | 2015-06-03 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| WO2005078848A2 (en) | 2004-02-11 | 2005-08-25 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes |
| US7622301B2 (en) * | 2004-02-24 | 2009-11-24 | Basf Plant Science Gmbh | Compositions and methods using RNA interference for control of nematodes |
| US7608394B2 (en) * | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
| AU2005230936B2 (en) | 2004-03-26 | 2010-08-05 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
| AU2005229015C1 (en) | 2004-04-02 | 2013-01-17 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| PT1818405E (pt) | 2004-04-09 | 2015-10-20 | Monsanto Technology Llc | Composições e métodos para o controlo de infestações de plantas por insectos |
| WO2005105157A2 (en) | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Ofnew York | INHIBITION OF HAIRLESS PROTEIN mRNA |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| ATE501252T1 (de) | 2004-06-22 | 2011-03-15 | Univ Illinois | Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns |
| US7968762B2 (en) | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
| CA2579574A1 (en) | 2004-07-23 | 2007-01-04 | The University Of North Carolina At Chapel Hill | Methods and materials for determining pain sensitivity and predicting and treating related disorders |
| ATE518954T1 (de) | 2004-08-18 | 2011-08-15 | Lorus Therapeutics Inc | Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen |
| PL2444497T3 (pl) | 2004-09-24 | 2015-04-30 | Simplot Co J R | Wyciszanie genów |
| US20060247197A1 (en) | 2004-10-04 | 2006-11-02 | Van De Craen Marc | Method for down-regulating gene expression in fungi |
| CN101056534B (zh) * | 2004-10-13 | 2012-10-10 | 乔治亚大学研究基金会公司 | 抗线虫的转基因植物 |
| EP1807522B1 (en) | 2004-10-21 | 2013-11-20 | Venganza Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
| US8772254B2 (en) | 2004-10-25 | 2014-07-08 | Devgen N.V. | Method and constructs for delivering double stranded RNA to pest organisms |
| US20100170000A9 (en) | 2004-10-25 | 2010-07-01 | Devgen Nv | Rna constructs |
| ES2343746T3 (es) | 2005-01-07 | 2010-08-09 | Diadexus, Inc. | Composiciones de anticuerpo ovr110 y metodos de uso. |
| US8088976B2 (en) * | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| DE202005004135U1 (de) * | 2005-03-11 | 2005-05-19 | Klocke Verpackungs-Service Gmbh | Mehrkomponentenverpackung mit Applikator |
| EP2360249A1 (en) | 2005-03-31 | 2011-08-24 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| CA2605508A1 (en) | 2005-05-12 | 2006-11-23 | Wisconsin Alumni Research Foundation | Blockade of pin1 prevents cytokine production by activated immune cells |
| EP1907546A2 (en) * | 2005-05-31 | 2008-04-09 | Devgen N.V. | Rnai for control of insects and arachnids |
| WO2007011702A2 (en) | 2005-07-15 | 2007-01-25 | The University Of North Carolina At Chapel Hill | Use of egfr inhibitors to prevent or treat obesity |
| ATE548459T1 (de) | 2005-09-16 | 2012-03-15 | Monsanto Technology Llc | Verfahren zur genetischen kontrolle von insektenbefall bei pflanzen und zusammensetzungen |
| EP2295584B1 (en) | 2005-09-16 | 2015-06-10 | deVGen N.V. | Transgenic plant-based methods for plant pests using RNAi |
| PT2270181E (pt) | 2005-09-16 | 2016-01-26 | Devgen Nv | Arncd como agente de controlo de insetos |
| WO2007039454A1 (en) | 2005-09-20 | 2007-04-12 | Basf Plant Science Gmbh | Methods for controlling gene expression using ta-siran |
| US9286469B2 (en) * | 2005-12-16 | 2016-03-15 | Cisco Technology, Inc. | Methods and apparatus providing computer and network security utilizing probabilistic signature generation |
| US20090012029A1 (en) * | 2006-01-06 | 2009-01-08 | Hussey Richard S | Cyst Nematode Resistant Transgenic Plants |
| JP5474356B2 (ja) | 2006-01-12 | 2014-04-16 | デブジェン エヌブイ | ＲＮＡｉを使用する害虫を制御する方法 |
| US8906876B2 (en) | 2006-01-12 | 2014-12-09 | Devgen Nv | Methods for controlling pests using RNAi |
| EP2348115A3 (en) | 2006-01-12 | 2012-01-18 | deVGen N.V. | Transgenic plant-based methods for plant pests using RNAi |
| US20080022423A1 (en) * | 2006-02-03 | 2008-01-24 | Monsanto Technology Llc | IN PLANTA RNAi CONTROL OF FUNGI |
| WO2007095469A2 (en) | 2006-02-10 | 2007-08-23 | Monsanto Technology Llc | Identification and use of target genes for control of plant parasitic nematodes |
| AU2007214547B2 (en) | 2006-02-13 | 2012-09-20 | Monsanto Technology Llc | Selecting and stabilizing dsRNA constructs |
| WO2007104570A2 (en) * | 2006-03-16 | 2007-09-20 | Devgen N.V. | Nematode control |
| WO2007123777A2 (en) | 2006-03-30 | 2007-11-01 | Duke University | Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses |
| PL216037B1 (pl) * | 2006-06-09 | 2014-02-28 | Inst Biotechnologii I Antybiotykow | Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor, komórka gospodarza oraz sposób otrzymywania polipeptydu |
| ES2479668T3 (es) | 2006-07-11 | 2014-07-24 | University Of Medicine And Dentistry Of New Jersey | Proteínas de reparación de la membrana celular, ácidos nucleicos que las codifican y métodos de uso asociados |
| CA2658786A1 (en) | 2006-07-28 | 2008-01-31 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| JP5391073B2 (ja) | 2006-11-27 | 2014-01-15 | ディアデクサス インコーポレーテッド | Ｏｖｒ１１０抗体組成物および使用方法 |
| CN101195821A (zh) * | 2006-12-04 | 2008-06-11 | 中国科学院上海生命科学研究院 | 利用RNAi技术改良植物抗虫性的方法 |
| EP2913341A1 (en) | 2006-12-22 | 2015-09-02 | University of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| CN101641010A (zh) | 2007-01-26 | 2010-02-03 | 路易斯维尔大学研究基金会公司 | 用作疫苗的外来体组分的修饰 |
| US20080184391A1 (en) * | 2007-01-29 | 2008-07-31 | Kuppuswamy Subramaniam | Pathogen resistant transgenic plants, associated nucleic acids and techniques involving the same |
| CN101646769A (zh) * | 2007-02-20 | 2010-02-10 | 孟山都技术公司 | 无脊椎动物微rna |
| DK2129680T3 (en) | 2007-03-21 | 2015-08-10 | Brookhaven Science Ass Llc | COMBINED hairpin ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF |
| US20100322949A1 (en) | 2007-04-26 | 2010-12-23 | Ludwig Institute For Cancer Research Ltd. | Methods for diagnosing and treating astrocytomas |
| EP2607477B1 (en) | 2007-05-03 | 2020-09-23 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
| CN107129957A (zh) * | 2007-06-29 | 2017-09-05 | 北京强新生物科技有限公司 | 促使长dsRNA可用于哺乳动物和其他所选动物细胞中的基因寻靶 |
| US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| CN101932708A (zh) | 2007-08-14 | 2010-12-29 | 联邦科学工业研究组织 | 改进的基因沉默方法 |
| KR101142209B1 (ko) | 2007-09-22 | 2012-05-04 | 재단법인서울대학교산학협력재단 | 섭취 ＲＮＡｉ를 이용한 꼬마선충에서 두 유전자의동시발현 억제방법 |
| US7968525B1 (en) | 2007-12-03 | 2011-06-28 | University Of Florida Research Foundation, Inc. | Use of RNA interference to validate new termiticide target sites and a method of termite control |
| CN102037123A (zh) | 2008-04-04 | 2011-04-27 | 卡兰多制药股份有限公司 | Epas1抑制剂的组合物和用途 |
| WO2009126896A2 (en) | 2008-04-10 | 2009-10-15 | Monsanto Technology Llc | Methods and compositions for root knot nematode control |
| GB0807018D0 (en) | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| EP2727996A1 (en) | 2008-11-06 | 2014-05-07 | The Johns-Hopkins University | Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors |
| US8735082B2 (en) | 2008-11-10 | 2014-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
| EP2379722B1 (de) | 2008-12-16 | 2016-09-07 | c-LEcta GmbH | Expressionsvektor |
| WO2010074783A1 (en) | 2008-12-23 | 2010-07-01 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
| JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
| MX2011009724A (es) | 2009-03-19 | 2011-10-14 | Merck Sharp & Dohme | Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia. |
| WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20110138223A (ko) | 2009-03-27 | 2011-12-26 | 머크 샤프 앤드 돔 코포레이션 | 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제 |
| US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
| EP2411018A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012521760A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20100257634A1 (en) * | 2009-04-03 | 2010-10-07 | Venganza Inc. | Bioassay for gene silencing constructs |
| US8283332B2 (en) | 2009-04-17 | 2012-10-09 | University Of Louisville Research Foundation, Inc. | PFKFB4 inhibitors and methods of using the same |
| EP2258858A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Transgenic LSD1 animal model for cancer |
| EP3000481A3 (en) | 2009-07-14 | 2016-05-11 | Mayo Foundation for Medical Education and Research | Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier |
| CN102481347A (zh) | 2009-07-24 | 2012-05-30 | 加州大学董事会 | 治疗和预防整合素αvβ5相关疾病的方法及组合物 |
| BR122018067960B8 (pt) * | 2009-08-28 | 2022-12-06 | Du Pont | Polinucleotídeo isolado, cassete de expressão, método para controlar uma praga de plantas do tipo coleoptera e método para obtenção de uma planta |
| AU2010328295B2 (en) | 2009-12-07 | 2015-09-10 | The Johns Hopkins University | SR-BI as a predictor of human female infertility and responsiveness to treatment |
| CN106701758B (zh) | 2009-12-09 | 2020-02-07 | 日东电工株式会社 | Hsp47表达的调节 |
| WO2011072243A1 (en) | 2009-12-10 | 2011-06-16 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
| US10640457B2 (en) | 2009-12-10 | 2020-05-05 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
| EP3406720A1 (en) | 2009-12-18 | 2018-11-28 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| KR101762466B1 (ko) | 2009-12-23 | 2017-07-27 | 노파르티스 아게 | 지질, 지질 조성물 및 이의 사용 방법 |
| MX344543B (es) | 2010-01-26 | 2016-12-19 | Nat Jewish Health | Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. |
| CA2789125A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
| CA2800065A1 (en) | 2010-05-21 | 2011-11-24 | Peptimed, Inc. | Reagents and methods for treating cancer |
| GB201009601D0 (en) | 2010-06-08 | 2010-07-21 | Devgen Private Ltd | Method for down-grading gene expression in fungi |
| WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
| JP6043285B2 (ja) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| EP3372684B1 (en) | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Single-stranded rnai agents containing an internal, non-nucleic acid spacer |
| EP2609106A4 (en) | 2010-08-26 | 2014-03-19 | Merck Sharp & Dohme | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20140134231A1 (en) | 2010-10-11 | 2014-05-15 | Sanford-Burnham Medical Research Institute | Mir-211 expression and related pathways in human melanoma |
| CN108404115A (zh) | 2010-10-15 | 2018-08-17 | 纽约市哥伦比亚大学理事会 | 肥胖症-相关的基因和它们的蛋白和其用途 |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| CA2816584A1 (en) | 2010-11-01 | 2012-05-10 | Peptimed, Inc. | Compositions of a peptide-based system for cell-specific targeting |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| HRP20191548T1 (hr) | 2010-11-02 | 2020-02-21 | The Trustees Of Columbia University In The City Of New York | Postupci liječenja poremećaja gubitka kose |
| US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
| EP2649181B1 (en) | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| ES2820863T3 (es) | 2010-12-22 | 2021-04-22 | Univ Columbia | Moduladores de histona acetiltransferasa y usos de los mismos |
| SG192961A1 (en) | 2011-03-03 | 2013-09-30 | Quark Pharmaceuticals Inc | Compositions and methods for treating lung disease and injury |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| EP2750767A4 (en) | 2011-09-02 | 2015-10-14 | Univ Columbia | CAMKII, IP3R, CALCINEURIN, P38 AND MK2 / 3 INHIBITORS FOR THE TREATMENT OF METABOLISM DISORDER IN CONNECTION WITH ADIPOSITAS |
| US9352312B2 (en) | 2011-09-23 | 2016-05-31 | Alere Switzerland Gmbh | System and apparatus for reactions |
| RS57645B1 (sr) | 2011-10-14 | 2018-11-30 | Hoffmann La Roche | Anti-htra1 antitela i načini primene |
| CN107266391B (zh) | 2011-10-18 | 2020-04-17 | 迪克纳制药公司 | 胺阳离子脂质及其用途 |
| KR101970034B1 (ko) | 2011-11-03 | 2019-04-17 | 쿠아크 파마수티칼스 인코퍼레이티드 | 신경보호를 위한 방법 및 조성물 |
| HUE040127T2 (hu) | 2012-03-29 | 2019-02-28 | Univ Columbia | Eljárások hajhullási rendellenességek kezelésére |
| UY34752A (es) | 2012-04-20 | 2013-11-29 | Futuragene Israel Ltd | Agentes para el control de la chinche del eucalipto |
| US20150082490A1 (en) | 2012-04-23 | 2015-03-19 | Futuragene Israel Ltd. | Glycaspis Brimblecombei Control Agents |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| WO2014018554A1 (en) | 2012-07-23 | 2014-01-30 | La Jolla Institute For Allergy And Immunology | Ptprs and proteoglycans in autoimmune disease |
| UY35064A (es) | 2012-10-03 | 2014-04-30 | Futuragene Israel Ltd | Agentes para el control de la avispa de las agallas |
| CA2886120A1 (en) | 2012-10-08 | 2014-04-17 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
| US9920316B2 (en) | 2013-03-14 | 2018-03-20 | Pioneer Hi-Bred International, Inc. | Compositions and methods to control insect pests |
| JP2016515508A (ja) | 2013-03-15 | 2016-05-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 融合タンパク質及びその方法 |
| EP2810952A1 (en) | 2013-06-03 | 2014-12-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Novel pest control methods |
| WO2015002969A1 (en) | 2013-07-03 | 2015-01-08 | City Of Hope | Anticancer combinations |
| EP3055426B1 (en) | 2013-10-09 | 2019-06-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
| JP6672156B2 (ja) | 2013-11-11 | 2020-03-25 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸（ｓｉＮＡ）の全身性送達 |
| US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| US10174111B2 (en) | 2013-12-27 | 2019-01-08 | National University Corporation Kochi University | Therapeutic drug for malignant tumors |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| WO2016059187A1 (en) * | 2014-10-16 | 2016-04-21 | Universite De Strasbourg | Method of capturing and identifying novel rnas |
| UA124449C2 (uk) | 2014-11-12 | 2021-09-22 | Нмк, Інк. | Трансгенна рослина з модифікованою редокс-залежною модуляцією пігментів фотосинтетичних антенних комплексів та спосіб її одержання |
| EP3925979A3 (en) | 2014-12-23 | 2022-03-23 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| WO2016145003A1 (en) | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Rna nanoparticle for treatment of gastric cancer |
| CN107429251A (zh) | 2015-03-09 | 2017-12-01 | 肯塔基大学研究基金会 | 用于治疗乳腺癌的miRNA |
| CN107531740B (zh) | 2015-03-09 | 2021-03-19 | 肯塔基大学研究基金会 | 用于脑肿瘤治疗的rna纳米颗粒 |
| US11279768B1 (en) | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
| CN107614685B (zh) | 2015-04-17 | 2021-10-19 | 肯塔基大学研究基金会 | Rna纳米颗粒及其使用方法 |
| WO2016176617A2 (en) | 2015-04-29 | 2016-11-03 | New York University | Method for treating high-grade gliomas |
| EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| US10072065B2 (en) | 2015-08-24 | 2018-09-11 | Mayo Foundation For Medical Education And Research | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier |
| AU2016321298A1 (en) | 2015-09-09 | 2018-03-29 | The Trustees Of Columbia University In The City Of New York | Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease |
| WO2017059118A1 (en) | 2015-09-29 | 2017-04-06 | Duke University | Compositions and methods for identifying and treating dystonia disorders |
| PE20181009A1 (es) | 2015-10-30 | 2018-06-26 | Genentech Inc | ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS |
| CN108367022A (zh) | 2015-12-13 | 2018-08-03 | 日东电工株式会社 | 具有高活性和降低脱靶的sirna结构 |
| US11072777B2 (en) | 2016-03-04 | 2021-07-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs) |
| JP7080179B2 (ja) | 2016-03-15 | 2022-06-03 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大に関する方法および組成物 |
| US10883108B2 (en) | 2016-03-31 | 2021-01-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
| EP3516062A1 (en) | 2016-09-21 | 2019-07-31 | Alnylam Pharmaceuticals, Inc. | Myostatin irna compositions and methods of use thereof |
| CN107858405B (zh) * | 2017-10-12 | 2021-09-24 | 华南农业大学 | 一种测定外源dsRNA对瓢虫毒性影响的方法 |
| WO2019199673A1 (en) | 2018-04-09 | 2019-10-17 | President And Fellows Of Harvard College | Modulating nuclear receptors and methods of using same |
| CN109266677B (zh) * | 2018-08-31 | 2021-11-23 | 中国烟草总公司郑州烟草研究院 | 一种全长转录因子酵母双杂交文库的构建方法 |
| CN109183158B (zh) * | 2018-08-31 | 2021-11-23 | 中国烟草总公司郑州烟草研究院 | 一种全长转录因子酵母单杂交文库的构建方法 |
| EP3853250A4 (en) | 2018-09-19 | 2022-06-08 | La Jolla Institute for Immunology | PTPRS AND PROTEOGLYCANS IN RHEUMATOID ARTHRITIS |
| TWI840449B (zh) | 2018-11-16 | 2024-05-01 | 日商日東電工股份有限公司 | 用於惡性腫瘤之rna干擾輸送配方及方法 |
| JP7317379B2 (ja) * | 2019-01-04 | 2023-07-31 | 国立大学法人京都大学 | 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法 |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| CN110229839B (zh) * | 2019-06-04 | 2021-06-08 | 中国农业大学 | 一种提升大肠杆菌dsRNA表达产率的方法 |
| CN110804088A (zh) * | 2019-11-18 | 2020-02-18 | 维塔恩(广州)医药有限公司 | 巨细胞病毒相关抗原短肽及其应用 |
| CN110746497A (zh) * | 2019-11-18 | 2020-02-04 | 维塔恩(广州)医药有限公司 | 肺炎衣原体相关抗原短肽及其应用 |
| EP3825408A1 (en) | 2019-11-19 | 2021-05-26 | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. | Methods of multi-species insect pest control |
| WO2021123920A1 (en) | 2019-12-18 | 2021-06-24 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| IL293530A (en) | 2019-12-18 | 2022-08-01 | Novartis Ag | Derivatives of 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione and their uses |
| EP4087652A1 (en) | 2020-01-08 | 2022-11-16 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| WO2021150300A1 (en) | 2020-01-22 | 2021-07-29 | Massachusetts Institute Of Technology | Inducible tissue constructs and uses thereof |
| US11642407B2 (en) | 2020-02-28 | 2023-05-09 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| CN113638055B (zh) * | 2020-05-22 | 2023-07-07 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种制备双链rna测序文库的方法 |
| WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
| WO2022269518A2 (en) | 2021-06-23 | 2022-12-29 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| EP4381069A1 (en) | 2021-08-02 | 2024-06-12 | Universite De Montpellier | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 |
| CN113533007B (zh) * | 2021-08-06 | 2023-11-24 | 青岛瑞斯凯尔生物科技有限公司 | 一种抗体染色标记装置及其方法 |
| IL311570A (en) | 2021-10-14 | 2024-05-01 | Arsenal Biosciences Inc | Immune cells with common expression chain and logic gate systems |
| EP4587571A2 (en) | 2022-09-13 | 2025-07-23 | Arsenal Biosciences, Inc. | Immune cells having co-expressed tgfbr shrnas |
| EP4587570A2 (en) | 2022-09-16 | 2025-07-23 | Arsenal Biosciences, Inc. | Immune cells with combination gene perturbations |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| WO2025199338A1 (en) | 2024-03-20 | 2025-09-25 | Arsenal Biosciences, Inc. | Systems targeting slc34a2 and tmprss4 and methods of use thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US589801A (en) * | 1897-09-07 | woltereck | ||
| EP0215907B1 (en) | 1985-03-21 | 2001-05-23 | Johnston, Stephen, Ph.D. | Parasite-derived resistance |
| US6608241B1 (en) | 1985-10-29 | 2003-08-19 | Monsanto Technology Llc | Protection of plants against viral infection |
| NZ219472A (en) | 1986-03-28 | 1990-08-28 | Calgene Inc | Regulation of phenotype in plant cells using dsdna constructs |
| US5017488A (en) * | 1986-04-01 | 1991-05-21 | University Of Medicine And Dentistry Of New Jersey | Highly efficient dual T7/T3 promoter vector PJKF16 and dual SP6/T3 promoter vector PJFK15 |
| US4970168A (en) * | 1989-01-27 | 1990-11-13 | Monsanto Company | Virus-resistant plants |
| EP0473576A4 (en) * | 1989-05-19 | 1993-03-10 | Hem Research, Inc. | Short therapeutic dsrna of defined structure |
| HUT57265A (en) | 1989-11-03 | 1991-11-28 | Zaadunie Bv | Process for producing plants of diminished infection-sensitivity |
| US5837848A (en) * | 1990-03-16 | 1998-11-17 | Zeneca Limited | Root-specific promoter |
| WO1991015111A1 (en) * | 1990-03-30 | 1991-10-17 | President And Fellows Of Harvard College | A binary genetic system to control expression of a transgene in a transgenic animal |
| US5831011A (en) * | 1990-07-27 | 1998-11-03 | Mycogen Corporation | Bacillus thuringiensis genes encoding nematode-active toxins |
| US5459252A (en) * | 1991-01-31 | 1995-10-17 | North Carolina State University | Root specific gene promoter |
| EP0631629B1 (en) | 1992-03-20 | 2003-12-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Fungus-responsive chimaeric gene |
| DE4234131C2 (de) * | 1992-10-09 | 1995-08-24 | Max Planck Gesellschaft | Transgener pathogen-resistenter Organismus |
| CA2088379A1 (en) * | 1993-01-29 | 1994-07-30 | University Of British Columbia | Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology |
| IL104830A (en) * | 1993-02-23 | 2001-01-28 | Yissum Res Dev Co | A chimeric plasmid containing a non-structural gene for the protease of the potato virus and its various uses |
| DE4317845A1 (de) | 1993-05-28 | 1994-12-01 | Bayer Ag | Desoxyribonukleinsäuren |
| US5482845A (en) * | 1993-09-24 | 1996-01-09 | The Trustees Of Columbia University In The City Of New York | Method for construction of normalized cDNA libraries |
| JPH10504448A (ja) * | 1994-06-15 | 1998-05-06 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 腫瘍抑制遺伝子を同定する方法 |
| US5691140A (en) * | 1995-05-18 | 1997-11-25 | New England Biolabs, Inc. | Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions |
| GB9510944D0 (en) * | 1995-05-31 | 1995-07-26 | Bogaert Thierry | Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour |
| DK0832207T3 (da) * | 1995-06-02 | 2000-11-06 | M & E Biotech As | Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer |
| US5679551A (en) * | 1995-10-31 | 1997-10-21 | Board Of Regents, The University Of Texas System | Unique double-stranded RNAS associated with the Trichomonas vaginalis virus |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| DE19631919C2 (de) * | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
| PL191777B1 (pl) * | 1996-08-09 | 2006-07-31 | Keygene Nv | Izolowany kwas nukleinowy, rekombinowany konstrukt DNA, wektor, plazmid, komórka bakterii, rekombinowany genom rośliny, komórki roślinne, roślina, nasiona transgeniczne, sposób otrzymywania roślin, sposób zabezpieczania roślin, sposób izolowania kwasu nukleinowego, sposób identyfikacji kwasu nukleinowego, kombinacja primerów, zestaw diagnostyczny, sposób detekcji, polipeptyd i RNA |
| EP0927262A1 (de) * | 1996-09-18 | 1999-07-07 | Christian Jung | Nematodenresistenzgen |
| EP0959120B1 (en) | 1996-10-03 | 2006-08-02 | Hajime Kato | Method for hydrocarbon steam reforming |
| AT409761B (de) | 1996-12-18 | 2002-11-25 | Exxon Chemical Patents Inc | Unter verwendung eines multifunktionellen mittels hergestellte kompatibilisierte polymermischungen |
| GB9703146D0 (en) | 1997-02-14 | 1997-04-02 | Innes John Centre Innov Ltd | Methods and means for gene silencing in transgenic plants |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| ATE507299T1 (de) * | 1998-04-08 | 2011-05-15 | Commw Scient Ind Res Org | Verfahren und mittel zum erhalt von veränderten phänotypen |
| AR020078A1 (es) * | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9814536D0 (en) | 1998-07-03 | 1998-09-02 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| AUPR621501A0 (en) | 2001-07-06 | 2001-08-02 | Commonwealth Scientific And Industrial Research Organisation | Delivery of ds rna |
| ATE548459T1 (de) | 2005-09-16 | 2012-03-15 | Monsanto Technology Llc | Verfahren zur genetischen kontrolle von insektenbefall bei pflanzen und zusammensetzungen |
-
1998
- 1998-12-09 GB GBGB9827152.1A patent/GB9827152D0/en not_active Ceased
-
1999
- 1999-07-02 HU HU0103571A patent/HU230602B1/hu not_active IP Right Cessation
- 1999-07-02 WO PCT/EP1999/004718 patent/WO2000001846A2/en not_active Ceased
- 1999-07-02 IL IL14046799A patent/IL140467A0/xx active IP Right Grant
- 1999-07-02 AT AT04011161T patent/ATE433500T1/de active
- 1999-07-02 DE DE69940984T patent/DE69940984D1/de not_active Expired - Lifetime
- 1999-07-02 ES ES04011161T patent/ES2327334T3/es not_active Expired - Lifetime
- 1999-07-02 DE DE69940219T patent/DE69940219D1/de not_active Expired - Lifetime
- 1999-07-02 JP JP2000558236A patent/JP4353639B2/ja not_active Expired - Fee Related
- 1999-07-02 AT AT01129274T patent/ATE419383T1/de active
- 1999-07-02 PL PL347978A patent/PL201425B1/pl unknown
- 1999-07-02 CZ CZ2012-309A patent/CZ304897B6/cs not_active IP Right Cessation
- 1999-07-02 PT PT01129274T patent/PT1197567E/pt unknown
- 1999-07-02 GB GB0118514A patent/GB2362885B/en not_active Expired - Fee Related
- 1999-07-02 CN CNB998101966A patent/CN1198938C/zh not_active Expired - Fee Related
- 1999-07-02 EP EP01129274.5A patent/EP1197567B2/en not_active Expired - Lifetime
- 1999-07-02 KR KR1020077005038A patent/KR20070041607A/ko not_active Ceased
- 1999-07-02 PL PL390495A patent/PL216779B1/pl unknown
- 1999-07-02 PT PT04011161T patent/PT1484415E/pt unknown
- 1999-07-02 NZ NZ509182A patent/NZ509182A/en not_active IP Right Cessation
- 1999-07-02 BR BR9911802-5A patent/BR9911802A/pt active Search and Examination
- 1999-07-02 CA CA2789083A patent/CA2789083C/en not_active Expired - Fee Related
- 1999-07-02 MX MXPA00012955 patent/MX234065B/es not_active IP Right Cessation
- 1999-07-02 DE DE29924298U patent/DE29924298U1/de not_active Expired - Lifetime
- 1999-07-02 EP EP10182431A patent/EP2374901A1/en not_active Withdrawn
- 1999-07-02 DK DK04011161T patent/DK1484415T3/da active
- 1999-07-02 AU AU49079/99A patent/AU769223B2/en not_active Ceased
- 1999-07-02 DE DE1093526T patent/DE1093526T1/de active Pending
- 1999-07-02 DE DE29924299U patent/DE29924299U1/de not_active Expired - Lifetime
- 1999-07-02 CZ CZ20010014A patent/CZ303494B6/cs not_active IP Right Cessation
- 1999-07-02 CN CN200510052742XA patent/CN1657620A/zh active Pending
- 1999-07-02 EP EP04011161A patent/EP1484415B1/en not_active Revoked
- 1999-07-02 EP EP99932836A patent/EP1093526A2/en not_active Withdrawn
- 1999-07-02 ES ES01129274.5T patent/ES2320527T5/es not_active Expired - Lifetime
- 1999-07-02 KR KR20047010184A patent/KR20040066200A/ko not_active Ceased
- 1999-07-02 KR KR1020017000068A patent/KR100563295B1/ko not_active Expired - Fee Related
- 1999-07-02 CN CNA2006100944808A patent/CN1900319A/zh active Pending
- 1999-07-02 GB GB0206600A patent/GB2370275B/en not_active Expired - Fee Related
- 1999-07-02 CA CA2332619A patent/CA2332619C/en not_active Expired - Fee Related
- 1999-07-02 RU RU2000133315/13A patent/RU2240349C2/ru not_active IP Right Cessation
- 1999-07-02 DK DK01129274.5T patent/DK1197567T4/en active
- 1999-07-02 KR KR1020067011420A patent/KR20060071438A/ko not_active Ceased
- 1999-07-02 PL PL384205A patent/PL213379B1/pl unknown
- 1999-07-02 EP EP08022353A patent/EP2045336A3/en not_active Withdrawn
- 1999-07-02 GB GB0020485A patent/GB2349885B/en not_active Expired - Fee Related
-
2000
- 2000-12-19 ZA ZA200007653A patent/ZA200007653B/en unknown
- 2000-12-21 IL IL140467A patent/IL140467A/en not_active IP Right Cessation
-
2001
- 2001-01-02 IN IN6DE2001 patent/IN2001DE00006A/en unknown
- 2001-01-02 NO NO20010019A patent/NO327729B1/no not_active IP Right Cessation
- 2001-01-02 IS IS5802A patent/IS2816B/is unknown
-
2002
- 2002-01-25 US US10/057,108 patent/US20030061626A1/en not_active Abandoned
-
2003
- 2003-12-17 US US10/738,886 patent/US20040133943A1/en not_active Abandoned
-
2004
- 2004-04-16 US US10/826,522 patent/US8114980B2/en not_active Expired - Fee Related
-
2006
- 2006-06-20 IN IN3568DE2006 patent/IN2006DE03568A/en unknown
-
2007
- 2007-03-06 IL IL181727A patent/IL181727A/en not_active IP Right Cessation
-
2009
- 2009-01-07 JP JP2009001591A patent/JP2009112311A/ja active Pending
- 2009-03-23 CY CY20091100345T patent/CY1108920T1/el unknown
- 2009-08-31 CY CY20091100907T patent/CY1109324T1/el unknown
-
2013
- 2013-09-09 JP JP2013186110A patent/JP5847776B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1197567B1 (en) | Characterisation of gene function using double stranded RNA inhibition | |
| Lozano et al. | Efficient gene targeting and removal of foreign DNA by homologous recombination in the picoeukaryote Ostreococcus | |
| US7005423B1 (en) | Characterization of gene function using double stranded RNA inhibition | |
| AU2004200852B2 (en) | Characterisation of gene function using double stranded RNA inhibition | |
| EP1815000A1 (en) | Enhancer-containing gene trap vectors for random and targeted gene trapping | |
| Deka | Gene cloning | |
| El Mouridi et al. | Targeted and random transposon-assisted single-copy transgene insertion in C. elegans | |
| Dinneen et al. | Universal Single Copy Knock-In System in Caenorhabditis elegans: One Plasmid to Target All Chromosomes | |
| McEachern | Inter-kingdom epigenetics: characterization of maize b1 tandem repeat-mediated silencing in Drosophila melanogaster |